Medlab Clinical Future Growth

Future criteria checks 2/6

Medlab ClinicalDie Gewinne des Unternehmens werden voraussichtlich um 44.7% pro Jahr sinken, während die jährlichen Einnahmen um 41.7% pro Jahr steigen werden. Der Gewinn pro Aktie wird voraussichtlich decline um 44.7% pro Jahr steigen.

Key information

-44.7%

Earnings growth rate

-44.7%

EPS growth rate

Biotechs earnings growth	16.3%
Revenue growth rate	41.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	04 May 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:MDC - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	4	-22	N/A	N/A	1
6/30/2023	7	-14	N/A	N/A	1
6/30/2022	2	-8	-9	-9	N/A
3/31/2022	1	-9	-10	-10	N/A
12/31/2021	4	-12	-11	-11	N/A
9/30/2021	4	-12	-11	-11	N/A
6/30/2021	1	-10	-10	-10	N/A
3/31/2021	1	-10	-9	-9	N/A
12/31/2020	1	-11	-8	-8	N/A
9/30/2020	2	-12	-10	-9	N/A
6/30/2020	3	-13	-11	-10	N/A
3/31/2020	4	-12	-11	-11	N/A
12/31/2019	4	-12	-12	-12	N/A
9/30/2019	5	-10	-11	-11	N/A
6/30/2019	5	-8	-11	-10	N/A
3/31/2019	5	-7	-9	-9	N/A
12/31/2018	5	-6	-7	-7	N/A
9/30/2018	4	-5	-6	-6	N/A
6/30/2018	4	-5	-5	-5	N/A
3/31/2018	4	-4	-5	-5	N/A
12/31/2017	5	-4	-5	-5	N/A
9/30/2017	5	-4	-4	-4	N/A
6/30/2017	4	-4	-4	-4	N/A
3/31/2017	4	-4	-4	-4	N/A
12/31/2016	4	-4	-4	-4	N/A
9/30/2016	3	-4	-4	-4	N/A
6/30/2016	3	-3	-4	-4	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: MDC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MDC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MDC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MDCDie Einnahmen des Unternehmens (41.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (4% pro Jahr).

Hohe Wachstumseinnahmen: MDCDie Einnahmen des Unternehmens (41.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MDC in 3 Jahren voraussichtlich hoch sein wird

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Medlab Clinical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

New 90-day high: AU$0.28

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.23

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies